Generating sufficient safety evidence would require large-scale clinical trials involving thousands of participants
GLP-1 medications (glucagon-like peptide-1 receptor agonists) are prescription medicines such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), and dulaglutide (Trulicity) that help control blood sugar and support weight loss
Users often experience their most significant improvements during this period, including enhanced range of motion, reduced morning stiffness, and improved overall quality of life
In gentle use, the difference might be small
The findings highlight a challenge as peptides become more mainstream: understanding what level of evidence exists for a given peptide and how its being sourced, prescribed, and monitored